Cannabinoid Nano-Encapsulation for Atopic Dermatitis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for atopic dermatitis are inadequate in effectively addressing the inflammation and symptoms of the condition, particularly in terms of skin penetration and systemic absorption of cannabinoids.
Innovation Solution
A topical composition containing cannabidiol (CBD) and cannabigerol (CBG) at 3% to 20% by weight, potentially with a ratio of CBG to CBD of 2:1, combined with oral administration of CBD through chewing gum, is applied twice daily for six weeks to treat atopic dermatitis, utilizing nano- or micro-encapsulation and incorporating hyaluronic acid derivatives and plant extracts for enhanced efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If topical composition with cannabinoids is applied to treat atopic dermatitis, then skin inflammation is reduced, but skin penetration and systemic absorption are insufficient
Solution Approach 1:
The patent changes the physical and chemical parameters of cannabinoid delivery by using nano-encapsulation (reducing particle size to nanoscale) and micro-encapsulation techniques. This transformation allows the cannabinoids to penetrate the skin barrier more effectively while maintaining controlled release properties, thereby improving both skin penetration and treatment efficacy simultaneously
Solution Approach 2:
The patent creates composite formulations by combining cannabinoids with hyaluronic acid derivatives and plant extracts in a topical composition. This composite approach enhances skin penetration through the synergistic effects of multiple components while improving overall treatment efficacy for atopic dermatitis
2Reliability
If higher concentrations of CBD/CBG oil are used, then treatment efficacy increases, but composition complexity increases
Solution Approach 1:
The patent applies local quality by creating specific ratio formulations of CBD and CBG (e.g., 2:1 ratio) tailored for atopic dermatitis treatment. This targeted approach allows higher effective concentrations of specific cannabinoids while maintaining formulation simplicity through defined ratios rather than complex mixtures
Solution Approach 2:
The patent standardizes the cannabinoid concentration parameters within specific ranges (3% to 20% by weight) and uses nano-encapsulation to maintain stability. This parameter optimization allows high efficacy concentrations while simplifying the formulation process through defined concentration ranges and standardized preparation methods
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The treatment shows significant improvement in atopic dermatitis symptoms, with higher concentrations of CBD/CBG oil demonstrating a clear dose-response effect and increased efficacy when combined with oral CBD administration, suggesting a synergistic role in restoring the Th1/Th2 balance and reducing skin inflammation.
Implementation Method 1
utilizing nano- or micro-encapsulation
Implementation Method 2
utilizing nano- or micro-encapsulation
Implementation Method 3
incorporating hyaluronic acid derivatives for enhanced efficacy
Data Source
AI summary
A method to treat the skin condition atopic dermatitis is described in this invention. The method comprises topical application of a composition containing cannabinoids, specifically cannabidiol and cannabigerol at a concentration of 3%-20% by weight of the composition. The method may further comprise administering chewing gum containing cannabinoids such as cannabidiol. Cannabidiol and cannabigerol may be sourced naturally or synthetically.